Proinflammatory IgG Fc structures in patients with severe COVID-19.
Journal
Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
31
08
2020
accepted:
26
10
2020
pubmed:
11
11
2020
medline:
26
1
2021
entrez:
10
11
2020
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 infections can cause coronavirus disease 2019 (COVID-19), which manifests with a range of severities from mild illness to life-threatening pneumonia and multi-organ failure. Severe COVID-19 is characterized by an inflammatory signature, including high levels of inflammatory cytokines, alveolar inflammatory infiltrates and vascular microthrombi. Here we show that patients with severe COVID-19 produced a unique serologic signature, including an increased likelihood of IgG1 with afucosylated Fc glycans. This Fc modification on severe acute respiratory syndrome coronavirus 2 IgGs enhanced interactions with the activating Fcγ receptor FcγRIIIa; when incorporated into immune complexes, Fc afucosylation enhanced production of inflammatory cytokines by monocytes, including interleukin-6 and tumor necrosis factor. These results show that disease severity in COVID-19 correlates with the presence of proinflammatory IgG Fc structures, including afucosylated IgG1.
Identifiants
pubmed: 33169014
doi: 10.1038/s41590-020-00828-7
pii: 10.1038/s41590-020-00828-7
pmc: PMC8130642
mid: NIHMS1641466
doi:
Substances chimiques
Cytokines
0
FCGR3A protein, human
0
Immunoglobulin G
0
Interleukin-6
0
Receptors, IgG
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-73Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007290
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : R01AI139119
Pays : International
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : U19AI111825
Pays : International
Organisme : NIAID NIH HHS
ID : R01 AI127877
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI097092
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI111825
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI139119
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI130398
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : U54CA260517
Pays : International
Organisme : NCI NIH HHS
ID : U54 CA260517
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI057229
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001866
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI125567
Pays : United States
Commentaires et corrections
Type : UpdateOf
Références
Bournazos, S., Wang, T. T., Dahan, R., Maamary, J. & Ravetch, J. V. Signaling by antibodies: recent progress. Annu. Rev. Immunol. 35, 285–311 (2017).
doi: 10.1146/annurev-immunol-051116-052433
Wang, T. T. IgG Fc glycosylation in human immunity. Curr. Top. Microbiol Immunol. 423, 63–75 (2019).
pubmed: 30805712
Nimmerjahn, F. & Ravetch, J. V. Fc receptors as regulators of immunity. Adv. Immunol. 96, 179–204 (2007).
doi: 10.1016/S0065-2776(07)96005-8
Nimmerjahn, F. & Ravetch, J. V. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310, 1510–1512 (2005).
doi: 10.1126/science.1118948
Liu, W. et al. Detection of COVID-19 in children in early January 2020 in Wuhan, China. N. Engl. J. Med. 382, 1370–1371 (2020).
doi: 10.1056/NEJMc2003717
Xu, Y. et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat. Med. 26, 502–505 (2020).
doi: 10.1038/s41591-020-0817-4
Bi, Q. et al. Epidemiology and transmission of COVID-19 in 391 cases and 1,286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect. Dis. 20, 911–919 (2020).
doi: 10.1016/S1473-3099(20)30287-5
Dong, Y. et al. Epidemiology of COVID-19 among children in China. Pediatrics 145, e20200702 (2020).
Stadlbauer, D. et al. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production and test setup. Curr. Protoc. Microbiol. 57, e100 (2020).
doi: 10.1002/cpmc.100
Thulin, N. K. & Wang, T. T. Maternal anti-dengue IgG fucosylation predicts susceptibility to dengue disease in infants. Cell Rep. 31, 107642 (2020).
doi: 10.1016/j.celrep.2020.107642
Wang, T. T. et al. Anti-HA glycoforms drive B cell affinity selection and determine influenza vaccine efficacy. Cell 162, 160–169 (2015).
doi: 10.1016/j.cell.2015.06.026
Wang, T. T. et al. IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity. Science 355, 395–398 (2017).
doi: 10.1126/science.aai8128
Bakovic, M. P. et al. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J. Proteome Res. 12, 821–831 (2013).
doi: 10.1021/pr300887z
Chen, G. et al. Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. J. Proteomics 75, 2824–2834 (2012).
doi: 10.1016/j.jprot.2012.02.001
de Haan, N., Reiding, K. R., Driessen, G., van der Burg, M. & Wuhrer, M. Changes in healthy human IgG Fc-glycosylation after birth and during early childhood. J. Proteome Res. 15, 1853–1861 (2016).
doi: 10.1021/acs.jproteome.6b00038
Kapur, R. et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood 123, 471–480 (2014).
doi: 10.1182/blood-2013-09-527978
Li, T. et al. Modulating IgG effector function by Fc glycan engineering. Proc. Natl Acad. Sci. USA 114, 3485–3490 (2017).
doi: 10.1073/pnas.1702173114
Kramer, P. R., Winger, V. & Reuben, J. PI3K limits TNF-α production in CD16-activated monocytes. Eur. J. Immunol. 39, 561–570 (2009).
doi: 10.1002/eji.200838801
Bournazos, S., Wang, T. T. & Ravetch, J. V. In Myeloid Cells in Health and Disease: A Synthesis (Ed. Gordon, S.) Ch. 22 (ASM Press, 2016).
Yuan, M. et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630–633 (2020).
doi: 10.1126/science.abb7269
ter Meulen, J. et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 3, e237 (2006).
doi: 10.1371/journal.pmed.0030237
Bournazos, S. & Ravetch, J. V. Fcγ receptor pathways during active and passive immunization. Immunol. Rev. 268, 88–103 (2015).
doi: 10.1111/imr.12343
Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. USA 114, E7348–E7357 (2017).
doi: 10.1073/pnas.1707304114
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
doi: 10.1126/science.abb2507
Wilk A. J. et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med. 26, 1070–1076 (2020).
Jagannathan, P. et al. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: a randomized controlled trial. PLoS Med. 15, e1002606 (2018).
doi: 10.1371/journal.pmed.1002606